-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:CRH公佈了強勁的2026年第一季業績,營收達74億美元(年成長9.1%,高於市場預期4.2%),調整後EBITDA超出市場預期9.2%,年成長18.4%至6億美元,利潤率提升70個基點至8.0%。公司多角化的產品組合策略帶來了差異化的績效表現,其中美洲材料解決方案業務營收成長21%,EBITDA成長75%;國際解決方案業務EBITDA成長32%,利潤率提升130個基點。管理層重申了2026年業績指引,預計淨利潤為39億至41億美元,調整後EBITDA為81億至85億美元。 CRH採取了積極的資本配置策略,包括19億美元的資產剝離和9億美元的收購,其中還包括即將完成的7億美元Axius Water收購案。我們預計,由於利率上升和燃料價格可能引發通膨,住宅市場將繼續面臨融資限制的挑戰。強勁的現金流使得公司得以將股利提高5%,並啟動3億美元的股票回購計劃,但淨負債也因此增至158億美元,槓桿率為2.0倍。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%